BioSpace News Archive

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”) today announces it plans to issue its fiscal first quarter 2020 earnings press release on Tuesday, July 14, 2020, after U.S. markets close, commensurate with the filing of its unaudited financial results

– Positive Scientific Opinion Under Early Access to Medicines Scheme (EAMS) Will Make Lumasiran Treatment Available for UK Primary Hyperoxaluria Type 1 (PH1) Patients Before Marketing Authorization -- – Lumasiran Indicated Within EAMS for the Treatment of Patients with PH1 --

Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels Data confirm Phase 3 study design to treat acute bleeding events in hemophilia

Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned clinical trial testing of Brilacidin, administered intravenously (IV), for the treatment of COVID-19. The exigencies of the pandemic coupled with Brilacidin’s multiple therapeutic properties – its anti-viral SARS-CoV-2 activity, its anti-inflammatory potential to abate the COVID-19 associated cytokine

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), announced that today Chief Executive Officer Michael Poirier has issued a letter to Qualigen’s stockholders. The full text of that letter is as follows: To My Fellow Stockholders, Many of you likely saw last week’s exciting announcement that Qualigen

BioReference initiates COVID-19 testing for all National Basketball Association players and referees, as well as team and league staff for its season restart in Orlando on July 30

ARS Pharmaceuticals today announced that on June 16, 2020 , the United States Patent and Trademark Office issued a second key patent for ARS-1, a low dose intranasal epinephrine nasal spray curr

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Zepzelca™ (lurbinectedin) was added by the National Comprehensive Cancer Network (NCCN®) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for small cell lung cancer (SCLC) on July 7, 2020.

Soleo Health, an innovative leader and national provider of complex specialty pharmacy and infusion services, announced today the capabilities of its new Soleo Direct™ program.

Cibus, a pioneer of precision gene editing in agriculture, announced the appointment of former Internal Counsel, Rosa Cheuk Kim, to Vice President, Legal. In her elevated role, Cheuk Kim will oversee all legal activities at Cibus, including intellectual property, contracts and litigation.